Timberlyne Therapeutics: Funding, Investors & Team (Oct 2026)
Timberlyne Therapeutics is a biopharmaceutical company in the clinical stage that specializes in creating and selling groundbreaking medications for autoimmune diseases. The company uses its team's expertise in drug development to acquire high-quality assets that target promising areas and apply them to medical conditions with significant gaps in treatment options.
Timberlyne Therapeutics has raised $180M across 1 funding round on record, the most recent a Series A of $180M announced in Jan 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Timberlyne Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Timberlyne Therapeutics Funding Rounds
Timberlyne Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Timberlyne Therapeutics Funding Compared to Other Biotechnology Startups
Timberlyne Therapeutics' latest round of $180M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Timberlyne Therapeutics in Biotechnology and San Diego
Companies Similar to Timberlyne Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Timberlyne Therapeutics Funding FAQs
What does Timberlyne Therapeutics do?
Timberlyne Therapeutics is a biopharmaceutical company in the clinical stage that specializes in creating and selling groundbreaking medications for autoimmune diseases. The company uses its team's expertise in drug development to acquire high-quality assets that target promising areas and apply them to medical conditions with significant gaps in treatment options.
How much funding has Timberlyne Therapeutics raised?
Timberlyne Therapeutics has raised $180M across 1 round on record. The most recent is a Series A of $180M announced in Jan 2025.
When did Timberlyne Therapeutics last raise funding?
Timberlyne Therapeutics' most recent funding round on record is a Series A of $180M, announced in Jan 2025.
Who founded Timberlyne Therapeutics?
FundedIQ lists Christian Fougner (Founder) at Timberlyne Therapeutics.
Where is Timberlyne Therapeutics headquartered?
Timberlyne Therapeutics is based in San Diego, California, United States.
How many employees does Timberlyne Therapeutics have?
Timberlyne Therapeutics is in the 11-50 employee band.
How does Timberlyne Therapeutics' funding compare to other Biotechnology startups?
Timberlyne Therapeutics' latest round of $180M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Timberlyne Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Timberlyne Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.